Investors in Sangamo Therapeutics (NASDAQ:SGMO) from three years ago are still down 90%, even after 13% gain this past week

Sangamo Therapeutics' share price surged 116% in 3 months, despite a 90% drop over 3 years. Recent gains raise hope, but long-term revenue decline poses risks. Investors should consider diversification and company stability beyond short-term gains.